Cellular Biomedicine Group (NASDAQ: CBMG) 530 University Avenue
Palo Alto, CA
Phone: +1 650 566 5064
Cellular Biomedicine Group, Inc. is a development stage biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases.
Cellular Biomedicine Group (NASDAQ: CBMG) is a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. We are the result of the acquisition, transfer, commercialization and advancement of thirty years of research and human treatment experience in cellular medicine. Our cellular research and development comes from collaboration among scientists and doctors from the US, Europe and China.
Our primary target market is Greater China. Our first two therapy candidates are currently used to treat patients in research studies conducted in China. We are also engaged in a number of pre-clinical studies for other product or therapy candidates, which we believe have the potential to become safe and effective treatment options for a variety of degenerative and debilitating conditions. We believe that the results of our research studies will support expanded preclinical and clinical trials with a larger population of patients, which we expect to carry out through authorized treatment centers throughout Greater China. With the recent acquisition of AG, we added technical services revenue comprised of T Cells Receptor (“TCR”) clonality analysis technology and T Central Memory Cell (“Tcm”) and Dendritic Cell (“DC”) preparation methodologies. Knee Osteoarthritis (KOA)
Indication: Knee Osteoarthritis (KOA)
Technology Platform: Human Adipose-Derived Mesenchymal Progenitor Cells (haMPC)
Trial Phase: Clinical Trial Phase IIb, all patients completed treatment as of August 2014
Interim results from phase IIb clinical trial for KOA: klick here
Osteoarthritis is a degenerative disease of the joints. KOA is one of the most common types of osteoarthritis. Pathological manifestation of osteoarthritis is primarily local inflammation caused by immune response and subsequent damage of joints. Restoration of immune response and joint tissues are the objective of therapies.
According to International Journal of Rheumatic Diseases, 2011, 53% of KOA patients will degenerate to the point of disability. Conventional treatment usually involves invasive surgery with painful recovery and physical therapy. As drug-based methods of management are ineffective, the same journal estimates that some 1.5 million patients with this disability will degenerate to the point of requiring artificial joint replacement surgery every year. However, only 40,000 patients will actually be able to undergo replacement surgery, leaving the majority of patients to suffer from a life-long disability due to lack of effective treatment.
haMPCs are currently being considered as a new and effective treatment for osteoarthritis, with a huge potential market. Osteoarthritis is one of the ten most disabling diseases in developed countries. Worldwide estimates are that 9.6% of men and 18.0% of women aged over 60 years have symptomatic osteoarthritis. It is estimated that the global OA therapeutics market was worth $4.4 billion in 2010 and is forecast to grow at a compound annual growth rate (“CAGR”) of 3.8% to reach $5.9 billion by 2018.
In order to bring haMPC-based KOA therapy to market, our market strategy is to: (a) establish regional laboratories that comply with cGMP standards in Shanghai and Beijing that meet Chinese regulatory approval; and (b) file joint applications with Class AAA hospitals (own commentary: press release from 09.02.2015 (klick here): We look forward to working with PLAGH as a long-term partner as we evaluate paths to commercialization,” commented Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group.) to use haMPCs to treat KOA in a clinical trial setting.
Our KOA therapy is not surgically invasive – it uses a small amount (30ml) of adipose tissue obtained via liposuction from the patient, which is cultured and re-injected into the patient. The injections are designed to induce the body’s secretion of growth factors promoting immune response and regulation, and regrowth of cartilage. The down-regulation of the patient’s immune response is aimed at reducing and controlling inflammation which is a central cause of KOA.
We believe our proprietary method, subsequent haMPC proliferation and processing know-how will enable haMPC therapy to be a low cost and relatively safe and effective treatment for KOA. Additionally, banked haMPCs can continue to be stored for additional use in the future. More products: klick here
Why CBMG? Annual report 31.03.2015:
In March 2015, the Company initiated a financing transaction pursuant to which it would sell up to 526,316 shares of the Company’s common stock, to selected investors at $38 per share, for total gross proceeds of approximately $20,000,000. The Shares were sold pursuant to separate subscription agreements between the Company and each Investor. Up to the issuance of the financial statements, $20,000,000 (unaudited) were received from investors.